Literature DB >> 1163442

Effects of intravenous verapamil on cardiac arrhythmias and on the electrocardiogram.

M K Heng, B N Singh, A H Roche, R M Norris, C J Mercer.   

Abstract

The effects of intravenous verapamil on the electrocardiogram in 15 patients with heart disease in sinus rhythm and in 44 patients with supraventricular and ventricular tachyarrhythmias were evaluated. Verapamil prolonged the P-R interval without effect on the QRS duration or the Q-Tc interval. In patients with atrial flutter and fibrillation, A-V block was increased, with slowing of the ventricular rate, in almost all cases but sinus rhythm was restored in only 1 of 12 patients in atrial fibrillation and in 2 of the 11 patients with flutter. Verapamil had no effect in 3 patients with atrial fibrillation complicating WPW syndrome; in 1 of 5 patients with ventricular tachycardia it caused reversion to sinus rhythm. Sinus rhythm was restored promptly by verapamil in 13 of 17 patients with paroxysmal supraventricular tachycardias; in 2 others, sinus rhythm became established 1 to 2 hours after administration of the drug. Transient hypotension, not requiring treatment, was the only side effect noted but not in the patients with supraventricular tachycardias, in whom blood pressure generally increased after reversion to sinus rhythm by verapamil.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1163442     DOI: 10.1016/0002-8703(75)90431-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  17 in total

1.  The effects of verapamil on cerebrospinal fluid pressure in surgical patients.

Authors:  T Nishikawa; A Namiki
Journal:  J Anesth       Date:  1987-09-01       Impact factor: 2.078

Review 2.  Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance.

Authors:  S Nattel
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Digitalis and verapamil in atrial fibrillation and flutter. Is verapamil now the preferred agent?

Authors:  H O Klein; E Kaplinsky
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 4.  The pharmacologic treatment of atrial fibrillation.

Authors:  R Bolognesi
Journal:  Cardiovasc Drugs Ther       Date:  1991-06       Impact factor: 3.727

Review 5.  New antiarrhythmic drugs: their place in therapy.

Authors:  D L Keefe; R E Kates; D C Harrison
Journal:  Drugs       Date:  1981-11       Impact factor: 9.546

6.  Antiarrhythmic drugs: clinical pharmacology and therapeutic uses.

Authors:  J L Anderson; D C Harrison; P J Meffin; R A Winkle
Journal:  Drugs       Date:  1978-04       Impact factor: 9.546

Review 7.  Role of calcium antagonists in cardiovascular therapy.

Authors:  H Dargie; E Rowland; D Krikler
Journal:  Br Heart J       Date:  1981-07

Review 8.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

Review 9.  Verapamil in arrhythmia.

Authors:  D M Krikler
Journal:  Br J Clin Pharmacol       Date:  1986       Impact factor: 4.335

Review 10.  Verapamil: a review of its pharmacological properties and therapeutic use.

Authors:  B N Singh; G Ellrodt; C T Peter
Journal:  Drugs       Date:  1978-03       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.